...NNZ-2566 for up to 28 days were well tolerated with no safety concerns identified. High-dose NNZ-2566... ...of Motor Behavior Assessment Change Index, CGI-I and Caregiver Top 3 Concerns scores. Additionally, high-dose NNZ-2566... ...score and Modified Apnea Index scores. Neuren said that the magnitude of improvement with low-dose NNZ-2566...
...single bolus injection of 20 mg/kg NNZ-2566 followed by an IV infusion of 6 mg/kg/hour NNZ-2566... ...more robust dataset (see BioCentury, May 14). Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
...evaluate a 20 mg/kg bolus of NNZ-2566 followed by a 6 mg/kg/hour IV infusion of NNZ-2566... ...more robust dataset (see BioCentury, May 14). Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
...Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566 Business: Inflammation Molecular target: Not available Description... ...data Milestone: Start Phase II (mid-2008) In an Australian Phase Ib trial in 28 volunteers, NNZ-2566... ...tolerated at all 4 dose levels. All patients received a 10-minute infusion of 20 mg/kg NNZ-2566...
...Australian and New Zealand Phase II trial in 60-70 patients to evaluate a bolus of NNZ-2566... ...by an IV infusion for 12-24 hours. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
...In a dose-escalation, Australian Phase I trial in 28 healthy volunteers, NNZ-2566 was safe at the... ...longer infusions of 12 or 24 hours. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...